About Aurobindo Pharma Limited

Aurobindo Pharma Limited established its headquarters in Hyderabad during 1986 as an international pharmaceutical organization which develops and produces generic and specialty pharmaceuticals and injectables and active pharmaceutical ingredients (APIs). The company maintains operations across 151 countries through its extensive network of manufacturing sites and business offices throughout the world. The company maintains operations in complex nasal and respiratory therapies and biosimilars and biologics contract manufacturing as well as API production. 

The company operates in six therapeutic areas which include Central Nervous System and Antiretrovirals and Cardiovascular and anti-infectives and anti-diabetics and cephalosporins. The company operates 33 facilities worldwide with 28 based in India and 5 located abroad as of March 31 2025. 

The Group maintains 87 subsidiaries together with joint ventures and associates which demonstrate its worldwide presence across multiple markets and value chains. The company achieved three major milestones through its continuous development of high-value complex generics and specialty products and its expanded API manufacturing capabilities and biosimilars and biologics CMO services for better supply stability and higher profit margins.

Aurobindo Pharma Limited’s Business Segments

The company generated 86% of its revenue from Formulations while APIs made up the remaining 14% of total revenue. The company generated 89% of its revenue from export activities while domestic sales accounted for 11% of total turnover.

Aurobindo Pharma Limited Key Management

• K. Nithyananda Reddy serves as Vice Chairman and Managing Director of the company.
• M. Madan Mohan Reddy serves as the Director (Whole-time Director) of the company.
• Santhanam Subramanian serves as the Chief Financial Officer of the organization.
• B. Adi Reddy serves as the Company Secretary.

Latest Updates on  Aurobindo Pharma Limited

• The Company received 31 final ANDA approvals from the US FDA including three specialty products and launched 33 products in the USA during the year. CuraTeQ Biologics received two EMA biosimilar approvals for filgrastim and pegfilgrastim and one MHRA approval for bevacizumab while its trastuzumab biosimilar received Indian manufacturing authorization and EU CHMP approval for marketing authorization.
• Aurobindo Pharma established its China oral solid dosages plant for commercial operations which produces 2 billion units annually. The US-based facilities in Raleigh have started producing topicals while the company continues to expand into additional product categories. The company operates at a total capacity of 60+ billion doses in formulations and 19,000 MT in APIs which demonstrates its extensive capabilities in FDF and API manufacturing.
• The Company holds a 10. The Company holds a 10.6% market share in the US prescription volume according to IQVIA TRx data for the quarter ending March 2025 while having filed 861 ANDAs and receiving 690 final approvals and 29 tentative approvals.
• Aurobindo operates in ten EU/UK countries and maintains a position among the top ten generic companies in eight of these markets through pharmacy and hospital and tender distribution channels.
• The Company initiated its first share buyback program by purchasing 51,36,986 shares at Rs 1,460 per share for a total expenditure of Rs 930 crore.
• Purple Bellflower (Pty) Ltd South Africa joined the company as a subsidiary through its acquisition on April 30 2024 to enhance operations in Africa.
• The Apitoria units received multiple CII national awards for energy excellence and EHS performance which demonstrated their operational excellence and quality systems. The biologics facility at CuraTeQ received EU-GMP certification in November 2024 following an EMA inspection during April 2024.